



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 19314

Title: Cancer immunotherapy for pancreatic cancer utilizing the α -gal epitope/natural anti-Gal antibody reaction

Reviewer's code: 00043819

Reviewer's country: Italy

Science editor: Ya-Juan Ma

Date sent for review: 2015-05-09 15:54

Date reviewed: 2015-05-24 23:02

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This is an interesting topic. The manuscript is well-written, and the literature review is good. I think the clinical implication of this cancer immunotherapy model should be emphasized, and more discussed, in particular in the adjuvant setting after tumor's resection.



ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 19314

Title: Cancer immunotherapy for pancreatic cancer utilizing the alpha-gal epitope/natural anti-Gal antibody reaction

Reviewer's code: 03088509

Reviewer's country: United States

Science editor: Ya-Juan Ma

Date sent for review: 2015-05-09 15:54

Date reviewed: 2015-05-29 00:41

Table with 4 columns: CLASSIFICATION, LANGUAGE EVALUATION, SCIENTIFIC MISCONDUCT, CONCLUSION. It contains checkboxes for various quality grades and misconduct types like Google Search, Duplicate publication, and Plagiarism.

COMMENTS TO AUTHORS

In this manuscript the authors review the literature on anti-gal antibodies in immunotherapy for pancreatic cancer. Most of the review is extensive and well written. However, the inclusion of experimental data towards the end of the manuscript is confusion. The experiments included use of a NOD-SCID animal model to test gal-tumor lysate as a vaccine. In the light of severely compromised immune system, interpretation of the data is difficult. Based on the findings the authors go on to propose use of murine tumors as vaccination material in patients. Without adequate experimental evidence, the suggestion is premature. The review would be most appropriate with previously unpublished data taken out. Other concerns are listed below: 1) On page 10, information in the text pertaining to Figure 1, should be clearly apparent in the Figure. For instance, include labels for MDSCs and dendritic cells. 2) The section on reciprocal distribution of anti-gal antibodies... on page 11 would be better organized with the sentence in page 12, lines 9-11 moved to the introduction of the section. 3) The text in several figures is difficult to read. For instance, the text in the green box of Figure 2 is unclear. 4) In Figure legend 3 and elsewhere in the text, add the word "antibody" next to



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

anti-gal for clarity.